We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Priaxon Appoints Dr Constance Hoefer as Chief Development Officer
News

Priaxon Appoints Dr Constance Hoefer as Chief Development Officer

Priaxon Appoints Dr Constance Hoefer as Chief Development Officer
News

Priaxon Appoints Dr Constance Hoefer as Chief Development Officer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Priaxon Appoints Dr Constance Hoefer as Chief Development Officer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Priaxon AG has announced the appointment of Dr Constance Hoefer as Chief Development Officer (CDO) of the Company. At Priaxon AG, Dr Hoefer will oversee the non-clinical and early clinical development.

Dr Hoefer has gained more than 20 years of international non-clinical development and management experience in academic and regulatory as well as industry roles in pharmaceutical and biotech companies. She started her industry career with Celltech in Cambridge, followed by increasingly responsible roles with Solvay Pharmaceuticals and Merck KGaA, before establishing an independent consultancy in 2006.

Since then, she has contributed her know-how and experience to national and international clients ranging from government institution spin-outs to national and international pharma clients. Most recently, she was Vice President and Head of Non-Clinical Development at Medigene AG.

Dr Christoph Burdack, CEO of Priaxon AG, said: "We are very pleased that Dr Hoefer is joining our Company at a time when Priaxon AG is entering a new and exciting phase. The Company has very promising candidates for oncology and autoimmune disease indications in early development. Dr Hoefer brings the necessary experience and knowledge for the Company to successfully advance Priaxon AG’s non-clinical programs towards the clinic."

“Priaxon AG’s development programs are a result of the application of innovative technologies and first class science to drug R&D, and have generated a number of exciting compounds for further development," stated Dr Constance Hoefer, Chief Development Officer at Priaxon AG. “I look forward to advancing these early assets through a focused but comprehensive non-clinical development program to enable a smooth and rational transition to clinical testing phases.”

Advertisement